Are You Confident of the Diagnosis?
Dermatophytoses are superficial fungal infections that are typically limited to the upper layer of the skin. Dermatophytes subsist on keratin debris. At any one time 1 in 5 Americans is affected by a dermatophyte infection.
Dermatophytes are divided into three groups. Anthropophilic dermatophytes are restricted to human hosts and produce a mild chronic inflammation. These include Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Trichophyton tonsurans. Zoophilic organisms are found mainly in animals and cause marked inflammation in humans with contact with infected dogs, cats, birds, farm animals (cattle, horses). These include Microsporum canis and Trichophyton verrucosum. Geophilic species can be found in the soil, but also in animals and humans, and cause significant inflammation that can lead to scarring. These include Microsporum gypseum.
Characteristic findings on physical examination
Tinea pedis, also known as “athlete’s foot,” is the most common presentation of a dermatophyte infection. Tinea pedis is dermatophyte infection involving the interweb spaces of the toes and the soles of the foot. It commonly presents as itchy scaly soles and itchy, fissured and macerated intertoe web spaces (
Tinea pedis may also present as inflammatory and blister-filled. This last presentation is often associated with an id reaction occurring on one or both hands. The least common presentation is one of ulceration. This can occur in the elderly or those with diabetes. Tinea manum is often a presentation of tinea pedis and is scaling and redness of one hand and two plantar surfaces. Often this is attributed to the transmission from the feet to the dominant hand by scratching and is known as “one hand two feet syndrome.”
Tinea cruris, also known as “jock itch,” is the second most common presentation of a dermatophyte infection. The most common clinical presentation is itchy, red, scaling patches in the intertriginous areas, which include the upper inner thigh, inguinal folds, perineal area and buttocks. Occasionally it will extend up on to the lower abdomen from the groin. The red scaly patches are usually bilateral.
Other details that are helpful include history of tight- fitting clothing, underwear or bathing suits and a hot humid environment. Multiple other diseases including intertrigo, inverse psoriasis, erythrasma, acanthosis nigricans can also occur in the folds. These can be distinguished by history and by performing fungal cultures or using potassium hydroxide to examine scraping as detailed below. Wood’s lamp examination is also helpful since erythrasma will fluoresce pink.
Tinea capitis is discussed in detail in the chapter entitled Tinea capitis/kerion.
Tinea corporis is a superficial dermatophyte infection that can affect any area of the body but typically excludes the glabrous skin of palms, soles, groin and scalp (
Since it can be passed from both humans and animals, exposure history through both travel and occupation should be evaluated for contact with infected humans or animals. Common exposures include people whose jobs have contact with animals (veterinarians, farmers, animal research technicians) and athletes who are involved in contact sports or have exposure to gyms.
A few clinical variants exists that are distinct. Tinea corporis gladiatorum occurs from skin-to-skin contact in wrestlers most commonly. Tinea imbricata is a form of tinea corporis that occurs in Southeast Asia and Central and South America and is clinically distinguished by concentric rings of erythema and scale. It is caused by Trichophyton concentricum. Majocchi’s granuloma is typically caused by Trichophyton rubrum and is a fungal infection in the hair follicles with a granulomatous reaction. Majocchi’s is discussed in more detail under unusual presentations below. The differential diagnosis of tinea corporis includes drug eruption, eczematous dermatitis, psoriasis, cutaneous lupus and secondary syphyllis.
Tinea unguium is a dermatophyte infection of the nail plate (
Tinea pedis with tinea unguium
Tinea barbae/tinea faciei are dermatophyte infections of the face. Tinea barbae typically affects the bearded area of men and tinea faciei (
Expected results of diagnostic studies
Scraping scale from the border to look under light microscopy using potassium hydroxide (KOH) results in identification of fungal elements. The KOH helps to dissolve keratin and leave the fungal elements intact. Fungal culture is more specific than KOH for detecting a dermatophyte infection. If suspicion is high and KOH is equivocal or negative, a fungal culture should be performed.
Fungal cultures can be grown on a number of media. The most common ones are Sabouraud agar, which contains agar and glucose but no antibiotics, Mycosel, which contains agar and antibiotics and dermatophyte test medium (DTM). DTM contains phenol red solution, which causes a color change from yellow to bright red under alkaline conditions and indicates a positive dermatophyte result. Polymerase chain reaction ( PCR) can also be used for fungal DNA identification. Confirmation can also be made by skin or nail plate biopsy. Septate branching hyphae can often be seen in the stratum corneum using special fungal stains including periodic acid-Schiff or Gomori methenamine silver on biopsied specimens.
Who is at Risk for Developing this Disease?
Tinea pedis is thought to be more common in men. It is also more common in hot humid environment, with the prolonged use of occlusive footwear especially plastic or rubber footwear as well as in those who share shoes, share public showers or have an increased tendency to sweat. Tinea pedis is more common in certain families and there appears to be predisposition in some individuals.
Tinea cruris affects mostly men with a 4:1 male to female ratio and has a peak incidence in men in their teens to thirties. The exact incidence is not known since it is under-reported. Affected men include athletes, those whose jobs require tight-fitted uniform and those living in hot humid environments. Additionally, the obese and those with diabetes are at increased risk. Chronic use of oral steroids and chronic immunosuppression in general is also thought to be a risk. Children do not commonly develop tinea cruris. Although it is often noted that patients with tinea cruris also have tinea pedis or onychomycosis, there are no studies to confirm this as a risk factor.
Tinea corporis is more common in warm humid environments and occurs in all age groups. There is some evidence that women who have increased contact with children are at increased risk. Additionally those in occupations that put them in contact with animals, athletes and children are at slightly increased risk. Immunocompromised patients are at increased risk for more disseminated disease and atypical presentations.
Tinea unguium risk factors include older age, history of tinea pedis, diabetes and poor-fitting shoes.
Tinea barbae commonly affects men whereas tinea faciei affects all ages and both sexes with peak incidence in children and in adults in their 20s to 40s. The most common sources of infection in the United States are pets (primarily cats and dogs). Those in frequent contact with pets and farm animals are at increased risk as are those with increased contact with children. Tinea barbae used to be a more common infection when razors were used without sterilization on multiple clients in a barber shop, but since the common practices of sterilization and single-use blades, this is a less frequent infection.
What is the Cause of the Disease?
At the national Centre for Mycology in Alberta, Canada, 58% of dermatophytes isolated are T rubrum, 27% are T mentagrophytes, 7% are T verrucosum and 3% are T tonsurans. In the United States there are higher percentages of T tonsurans isolated especially from tinea capitis. At the Center for Disease Control, the percentages for dermatophyte infections have not been estimated.
Tinea pedis is most commonly caused by T rubrum. Intertriginous and hyperkeratotic versions are typically caused by T rubrum. Bullous tinea pedis is more often caused by T mentagrophytes. E floccosum has also been reported to cause tinea pedis.
Tinea cruris is commonly caused by T rubrum or E floccosum.
Tinea corporis is most commonly caused by T rubrum ( some report it is responsible for close to 50% of all cases). There are increasing numbers caused by T tonsurans, T mentagrophytes and Microsporum canis. Rarer causes include T verrucosum, E floccosum and T violaceum.
Tinea unguium is most commonly caused by T rubrum, T tonsurans, T mentagrophytes, E floccosum.
Tinea barbae and faciei are commonly caused by M canis but have also been shown to be caused by T tonsurans, T rubrum and E floccosum. Rare cases can be caused by T schoenleinii.
All dermatophytes prefer to live in the cornified layers of the skin, which provide a warm, moist environment. Many dermatophytes invade in a centrifugal fashion. The epidermis proliferates as a defense and so the active edge of the infection is scaly and more inflammed while the central region has less scale.
Systemic Implications and Complications
Tinea infections in general do not have any systemic implications. They may be a sign of underlying diabetes or other immunosuppression but in the majority of cases it is just a result of having moist warm skin folds. No testing is necessary. Unusual presentations and extensive disease are most common in the immunosuppressed, so in a patient without a known history of immunosuppression and atypical presentation, HIV testing and appropriate cancer screening may be indicated.
Tinea faciei can result in scarring if infection is caused by T schoenleinii or zoophilic species. Scarring is a complication that can occur with tinea capitis as well, as discussed in the chapter on tinea capitis.
Tinea pedis may be treated topically or orally. Topical medications include topical imidazoles, pyridones, allylamines and benzylamines 1 to 2 times a day for up to 6 weeks but most commonly up to 2 weeks. Clotrimazole, which is a broad-spectrum anti-fungal agent that alters cell membrane permeability and causes death of fungal cells. Ketoconazole is a broad-spectrum imidazole that inhibits synthesis of ergosterol and causes the cellular components to leak, also resulting in death of fungal cells. Econazole also has some antibacterial activity so can be used when a mixed infection is suspected. Ciclopirox 1% cream is a topical pyridone that interferes with synthesis of DNA, RNA and proteins.
Topical allylamines include naftifine 1% cream and terbinafine topical. These may be effective in as little as 1 week. Terbinafine should not be used for more than 4 weeks. Hyperkeratotic tinea pedis usually requires a topical keratinolytic agent like urea or salicylic acid to remove the scale and allow the topical antifungal medications to penetrate.
Patients with severe inflammatory or bullous tinea pedis and those with underlying chronic disease like diabetes usually require a short course up to 2 weeks of oral antimycotics. Itraconazole, terbinafine and fluconazole should be considered in these patients as oral antimycotics. Aluminum acetate (Domeboro, Burrow’s solution) can also be used as a drying agent for bullous tinea pedis. Tablets should be diluted to 1:10 to 1:40 in water. Additionally keeping feet dry, wearing breathable shoes and using moisture wicking socks should be part of a treatment plan. Patients should also be encouraged not to share socks and shoes and to wear flip flops or foot covering while at public showers or pools.
Tinea cruris is typically treated topically since it is a localized infection. Over-the-counter products are available and are effective. Butenafine hydrochloride 1% is the ingredient found in Lotrimin Ultra and can be used once a day for 2 weeks in those over 12 years of age. The imidazole class including clotrimazole, ketoconazole, econazole can also be used twice a day for 2 weeks. Terbinafine topically can also be used 1 to 2 times a day in those over 12 years of age for 1 to 2 weeks. It is uncommon to require oral antifungal medications. Additional treatment includes discontinuing tight-fitted clothing, providing air to occluded skin folds and proper cleansing of uniforms and clothing. Weight loss can be part of an effective therapy for those with recurrent infection because of excessive moist wet folds in the setting of obesity.
Tinea corporis is usually treated with topical therapy since it is localized infection. Topical azoles and allylamines are recommended two times a day for a minimum of 2 weeks and should be applied to the area affected and an additional 1 to 2mm beyond the visibly infected area. Ciclopirox olamine also may be used. There is debate about whether topical steroids should be added to the treatment regimen. Low-potency steroids are sometimes recommended to relieve itch and erythema; however, prolonged use can lead to recurrent or persistent infections. If used at all, topical steroids should only be used for the first few days of treatment. It is not recommended to use the combination steroid/antifungal agents.
Systemic therapy may be necessary for disseminated disease or in immunocompromised individuals. Griseofulvin at 10mg/kg/day dosing can be used for 4 weeks. Alternatively systemic azoles like fluconzaole can be given at 50 to 100mg/day or 150mg once a week for 2 to 4 weeks. Itraconazole can be given at 100mg/day for 2 weeks. Oral terbinafine can also be used at 250mg/day for 2 weeks. Dosing should be adjusted in children.
Tinea unguium is usually treated orally. Topical therapy has little role in infection of the nail plate. Mycologic cure rates for ciclopirox (Penlac) nail lacquer, applied daily for up to 48 weeks, have ranged from 29% to 47%. Itraconazole and terbinafine have been studied for tinea unguium and can be used for 12 weeks at 200mg once a day for itraconazole and 250mg once a day for terbinafine in adults. Dose adjustments should be made for children (4 to 5mg/kg/day of terbinafine has been used successfully). Hepatic function should be followed at baseline and every 4 to 6 weeks when on this therapy. Griseofulvin is not often used since some studies show it is ineffective and may require 12 months of therapy.
Tinea faciei can usually be treated with topical anti-fungal therapy. Tinea barbae, because it involves invasion of the dermatophyte into the hair follicle, requires short courses of 4 to 6 weeks of oral antifungal therapy as detailed below.
Optimal Therapeutic Approach for this Disease
Topical and oral treatments for dermatophytosis are summarized in
Topical medications for dermatophyte infections
|Agent*||Formulation||Frequency and length of time of application|
|Naftifine (Naftin)||1% cream||Once daily for 2-4 weeks|
|FDA approved for treatment of tinea pedis, tinea cruris, tinea corporis caused by T rubrum, T mentagrophytes and E floccosum.|
|1% gel||Once or twice daily for 2-4 weeks|
|FDA approved for treatment of tinea pedis, tinea cruris, tinea corporis caused by Trichophyton Rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum.|
|Butenafine hydrochloride (Mentax, Lotrimin Ultra)||1% cream||Once or twice daily for 2-4 weeks|
|FDA approved for treatment of tinea pedis, tinea cruris|
|Clotrimazole (Lotrimin, Lotrimin AF)||1% cream, solution, or lotion||Twice daily for 2-4 weeks|
|FDA approved for treatment of tinea pedis, tinea cruris|
|One to two times daily for 2-4 weeks|
|Econazole (Spectazole)***||1% cream||FDA approved for treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.|
|Twice daily for 2 weeks|
|Ketoconazole (Nizoral)||1% cream||FDA approved for the treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; and in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); and in the treatment of cutaneous candidiasis caused by Candida spp.|
|Twice weekly for 2-4 weeks|
|1% shampoo||FDA approved for seborrheic dermatitis|
|Twice daily for 2 weeks|
|Ketoconazole (Ketoconazole, Xolegel, Extina)||2% cream 2% foam (Extina) 2% gel (Xolegel)||FDA approved for the treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; and in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); and in the treatment of cutaneous candidiasis caused by Candida spp.|
|Foam and gel have only been FDA approved for seborrheic dermatitis.|
|Once or twice daily for 2-4 weeks|
|Oxiconazole (Oxistat)||1% cream or lotion||FDA approved for the topical treatment of tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. Oxistat Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur|
|Once or twice daily for 2-4 weeks|
|Sulconazole (Exelderm)||1% cream or lotion||FDA approved for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Microsporum canis and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis.|
|Twice daily for for 2 weeks*****|
|Ciclopirox (Loprox)||1% cream or lotion||FDA approved for the treatment of tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.|
|Twice daily for 2-4 weeks|
|Tolnaftate (Tinactin)||1% cream, solution, or powder||FDA approved for the treatment of tinea pedis, tinea cruris and tinea corporis due to Trchophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum.|
Oral Therapy for Dermatophyte infection*
|Agent*||Dosage||Length of time of Administration|
|Terbinafine (Lamisil)||Children: <20kg 62.5mg, 20-40kg 125mg||Once daily for 2 weeks for tinea pedis, corporis, facei, 4-6 weeks for tinea capitis, tinea barbae, 12 weeks for onychomycosis|
|Oral granules are FDA approved for tinea capitis in children 4 years and older.|
|Adults (children >40kg) 250mg||Once daily for 2 weeks for tinea pedis, tinea corporis, tinea facei, 4-6 weeks for tinea capitis, tinea barbae, tinea incognito, 12 weeks for onychomycosis|
|Tablets FDA approved for treatment of tinea unguium.|
|Fluconazole||Children: 3-5mg/kg||Daily for 2-4 weeks for tinea corporis, cruris, facei, pedis|
|Adults: 50-150mg||Daily for 2-4 weeks for tinea corporis, cruris,facei, pedis|
|Alternate: Once a week for 4-6 weeks for tinea barbae, corporis,cruris, facei, pedis|
|FDA approved for treatment of vaginal candidiasis, oropharyngeal and esophageal candidiasis, candida urinary tract infections, peritonitis and systemic Candida infections and crytococcal menigitis.|
|Daily for 2-4 weeks for tinea corporis,cruris, facei, pedis|
|Itraconazole||Children: 3-5mg/kg**||Daily for 2 weeks for tinea corporis, cruris, facei; 12 weeks for onychomycosis|
|Adults: 200mg||FDA approved for the treatment of Blastomycosis, histoplasmosis, Aspergillosis as well as tinea unguium (onychomycosis caused by dermatophytes).|
|Daily for up to 4-6 weeks for recalitrant infection|
|Daily for 2-4 weeks for tinea corporis, cruris, facei, pedis|
|Ketoconazole||Children:3-5mg/kg||Daily for 4-6 weeks for tinea barbae|
|Adults:200-400mg||Tablets are indicated for the treatment of the following: systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush,candiduria, blastomycisus, coccidiomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis|
|Griseofulvin||10mg/kg||Daily for 2-4 weeks for Tinea corporis, Tinea facei, Tinea Pedis|
|20mg/kg||Daily for 6-8 weeks for Tinea capitis|
|FDA approved for the treatment of tinea capitis, tinea corporis, tinea pedis, tinea unguium, tinea cruris, tinea barbae caused by Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis, Trichophyton verrucosum,Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum, Epidermophyton floccosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform|
All patients with dermatophyte infection should be monitored for recurrence. For those with limited tinea pedis or tinea cruris, patients should be instructed to restart topical therapy at the first sign of recurrent infection. Over-the-counter topical therapy should be effective in about 2 weeks so persistent infections should be seen by dermatologists or primary care providers for assessment of disease, fungal cultures, alternate topical therapies or oral therapy. Maintenance therapy for those with tinea pedis or cruris includes keeping folded or occluded areas cool and dry.
Unusual Clinical Scenarios to Consider in Patient Management
Tinea incognito is a dermatophyte infection whose clinical appearance has been altered by application of topical steroids. It may present as inflammatory papules and pustules without the characteristic scale. Often it retains the scale but becomes bizarrely shaped. Often there is a history that the area keeps getting better with steroids and fading but never completely goes away. On the face it may have the appearance of rosacea or lupus erythematosus. On the body it often mimics impetigo, eczema, psoriasis or erythema migrans.
Use of topical steroids or oral steroids for tinea leads to the formation of deeper subcutaneous abscesses and secondary granuloma formation known as Majocchi’s granuloma. This type of deep infection can mimics Kaposi’s sarcoma. Once recognized, tinea incognito usually requires oral anti-fungal medications. Terbinafine, itraconazole and fluconazole have been shown to be superior to griseofulvin as they accumulate in the skin. Therapy for 2 to 4 weeks is typically required and can be combined with topical anti-fungal therapy.
Patients with HIV or who are immunocompromised often have atypical and severe presentations with either disseminated skin infection or other deep abscesses.
A form of tinea corporis exists that is caused by T violaceum and is composed of itchy purple macules is called tinea corporis purpurica.
Tinea facei caused by T schoenleinii can lead to scarring.
What is the Evidence?
Atanasovski, M, El Tal, AK, Hamzavi, F, Mehregan, DA. "Neonatal dermatophytosis: report of a case and review of the literature". Pediatr Dermatol. vol. 28. 2011. pp. 185-8.(This is a case report of a neonate with tinea capitis successfully treated with griseofulvin and topical ketoconazole shampoo. Includes a review of common dermatophyte infections of neonates.)
Budimulja, U, Bramono, K, Urip, KS, Basuki, S, Widodo, G, Rapatz, G, Paul, C. "Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study". Mycoses. vol. 44. 2001. pp. 300-306.(This study was carried out to determine the efficacy and tolerability of terbinafine 1% cream, applied once daily for 7 days, in adult patients with tinea corporis/cruris. In a multicenter, randomized, double-blind, parallel-group study, patients with a clinical diagnosis of tinea corporis/cruris confirmed by microscopy and culture received treatment with either terbinafine 1% cream [n = 57] or placebo cream [n = 60]. Terbinafine was significantly more effective than placebo in terms of clinical response, reduction in signs and symptoms scores, and overall efficacy.)
(This is a Web site linked to the main Centers for Disease Control Web site that discusses mycotic diseases.)
Del Boz, J, Crespo, V, Rivas-Ruiz, F, de Troya, M. "Tinea incognito in children: 54 cases". Mycoses. vol. 54. 2011. pp. 254-8.(The aim of this study was to analyze the main epidemiologic, clinical and microbiologic characteristics of TI diagnosed in children in comparison with other tineas. T mentagrophytes was the most common infection in 44% of the Spanish children reported in this study.)
Doncker, PD, Gupta, AK, Marynissen, G, Stoffels, P, Heremans, A. "Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview". J Am Acad Dermatol. vol. 37. 1997. pp. 969-74.(This was a review of the studies in which itraconazole pulse therapy (PT) has been administered in the management of dermatomycoses. For tinea pedis and manuum, the recommended dosage is itraconazole 200mg twice daily for 1 week (n = 220). A clinical response and mycologic cure rate of 90% +/- 4% and 76% +/- 6%, respectively, was obtained. For tinea corporis/cruris, itraconazole 200 mg/day for 1 week (n = 354) resulted in a clinical response and mycologic cure rate of 90% +/- 4% and 77% +/- 6%, respectively.When three pulses of itraconazole are used to treat toenail onychomycosis (n = 1389), the clinical cure rate, clinical response, and mycologic cure rate at follow-up 12 months after the start of therapy were 58% +/- 10%, 82% +/- 3%, and 77% +/- 5%, respectively.)
Erbagci, Z. "Topical therapy for dermatophytoses: should corticosteroids be included?". Am J Clin Dermatol. vol. 5. 2004. pp. 375-384.(This was a review article looking at corticosteroids including combination products. It concluded that combination products containing a low-potency nonfluorinated corticosteroid may initially be used for symptomatic inflamed lesions of tinea pedis, tinea corporis, and tinea cruris, in otherwise healthy adults with good compliance; therapy should be substituted by a pure antifungal agent once symptoms are relieved and should never exceed 2 weeks for tinea cruris and 4 weeks for tinea pedis/corporis; contraindications for the use of these combinations include application on diaper or other occluded areas and facial lesions, as well as in children younger than 12 years of age and in immunosuppressed patients for any reason.)
Gupta, AK, Cooper, EA. "Update in antifungal therapy of dermatophytosis". Mycopathologia. vol. 166. 2008. pp. 3533-3567.(This article reviews topical and oral therapy for dermatophytosis. It highlights that topical medications applied once or twice daily are the primary treatment indicated for tinea corporis/cruris, and tinea pedis/manuum. Use of oral antifungals occurs when the tinea involvement is extensive or chronic and for tinea unguium [onychomycosis] and tinea capitis. It also highlights relapse of infection as a problem with tinea pedis/unguium.)
Gupta, AK, Einarson, TR, Summerbell, RC, Shear, NH. "An overview of topical antifungal therapy in dermatomycoses". A North American perspective. Drugs. vol. 55. 1998. pp. 645-74.(This article reviews the epidemology of dermatophyte infections and highlights that for the treatment of tinea corporis, tinea cruris tinea versicolor and cutaneous candidosis, once or twice daily application is required, the most common duration of therapy being 2 to 4 weeks. For tinea pedis the most common treatment duration is 4 to 6 weeks.)
Kaviarasan, PK, Jaisankar, TJ, Thappa, DM, Sujatha, S. "Clinical variations in dermatophytosis in HIV infected patients". Indian J Dermatol Venereol Leprol. vol. 68. 2002. pp. 213-216.(This article highlights the high prevalence of dermatophyte infection in HIV patients and the unusual presentation and extensiveness of disease in this patient population.)
Lesher, JL. "Oral therapy of common superficial fungal infections of the skin". J Am Acad Dermatol. vol. 40. 1999. pp. S31-4.(This article gives a review of the effectiveness of the oral antifungal agents fluconazole, itraconazole, and terbinafine in the treatment of pityriasis versicolor, tinea corporis/cruris, and tinea pedis.)
Millikan, LE. Cutis. vol. 68. 2001. pp. 6-14.(This article reviews the need and use of oral antifungal therapy in immunocompromised patients. It highlights the safety and efficacy of terbinafine in these patients as one oral therapy.)
(This is Canada’s national center for mycology Web site. It provides details of common dermatophyte infection as well as the causative species in each type of infection.)
Patel, GA, Wiederkehr, M, Schwartz, RA. "Tinea cruris in children". Cutis. vol. 84. 2009. pp. 133-1377.(This article looks at tinea cruris in children. It highlights that the most common children with this type of infection are usually adolescent athletes. It does note that those with obesity and diabetes are at increased risk no matter the age.)
Rich, P, Houpt, KR, LaMarca, A, Loven, KH, Marbury, TC, Matheson, R, Miller, B, Smith, S, Wolf, J. "Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes". Cutis. vol. 68. 2001. pp. 15-22.(This paper reviews the safety of oral terbinafine in immunocompromised patients. It finds a short course of oral terbinafine 250mg once daily is a safe and effective treatment for tinea corporis or tinea cruris in subjects with HIV infection or diabetes.)
Stary, A, Sarnow, E. "Fluconazole in the treatment of tinea corporis and tinea cruris". Dermatology. vol. 196. 1998. pp. 237-41.(This is an open, noncomparative study of tinea corporis and cruris patients treated with once weekly fluconazole 150mg over 2 to 4 weeks. This regimen was shown to be efficacious and safe in the treatment of tinea corporis and cruris.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Self-Predictions for Well-Being Influence Satisfaction After Mastectomy, Breast Reconstruction
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Gabapentin Improves Postoperative Opioid Cessation, But Not Pain Resolution
- Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|